Welcome to our dedicated page for Cue Biopharma news (Ticker: CUE), a resource for investors and traders seeking the latest updates and insights on Cue Biopharma stock.
Cue Biopharma, Inc. reports developments in clinical-stage immunology therapeutics and immune-modulating biologics. Company updates center on its Immuno-STAT platform, the autoimmune and inflammatory disease candidate CUE-401, a clinical-stage dual-mechanism anti-IgE antibody for allergic diseases, and collaboration activity involving B cell depletion programs such as CUE-501.
Recurring news also covers leadership changes, inducement equity awards, shareholder-approved capital actions, research presentations, milestone payments, licensing activity, and other corporate matters tied to Cue Biopharma's Nasdaq-listed common stock and clinical-stage operating model.
Cue Biopharma (NASDAQ: CUE) announced a conference call and webcast for a business update on May 19, 2020, at 4:30 p.m. EDT. The event will provide insights into the company’s platform and pipeline advancements, alongside strategic objectives and milestones. Cue Biopharma, headquartered in Cambridge, Massachusetts, specializes in engineering injectable biologics to selectively engage T cells to combat cancer and autoimmune diseases using its proprietary Immuno-STAT™ platform. Investors can access the live event via the company’s website.